SUPN

Supernus, Inc.

$28.75

4.09%
SectorHealthcareIndustryDrug Manufacturers - Specialty & GenericCountryUnited States

Supernus, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.

Source: Yahoo Finance
AI summary

Price & performance

1M-33.6%
3M-38.8%
YTD-43.1%
1Y-49.5%
52-week range—
Beta0.54
Full chart and returns against a benchmark

Q-Score

59/ 100

Quality against peers; 50 is the peer median.

Growth57
Risk70
Performance48
Valuation61
Profitability58
Leverage54
Sentiment38
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$719M+8.6%
Net income-$38.6M-152.2%
Net margin-5.4%-16.5 pts
Historical fundamentals

Valuation

SUPNIndustryP/E—35.25P/S1.942.74EV/EBITDA29.0816.35P/B1.582.46PEG—0.87
Dividend yield0.00%
Every valuation metric

Earnings

Oct 29next report, after the close
EPS estimate$0.61
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate